Safety and efficacy of telbivudine for the treatment of chronic hepatitis B

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 789-798

  Osborn, Melissa K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antivirals; Hepatitis B; Resistance; Telbivudine

Indexed keywords

ADEFOVIR; CREATINE KINASE; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; ISOLEUCINE; LAMIVUDINE; METHIONINE; RNA DIRECTED DNA POLYMERASE; TELBIVUDINE; TENOFOVIR;

ADD ON THERAPY; ALGORITHM; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; CHRONIC HEPATITIS; CLINICAL PROTOCOL; CREATINE KINASE BLOOD LEVEL; CROSS RESISTANCE; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GENE MUTATION; HEART ARRHYTHMIA; HEPATITIS B; HISTOPATHOLOGY; HUMAN; LACTIC ACIDOSIS; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; MYOPATHY; NEURALGIA; OUTCOME ASSESSMENT; PARESTHESIA; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PROTEIN DOMAIN; REVIEW; SEROCONVERSION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS RESISTANCE;

EID: 76749091798     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s5318     Document Type: Review

References (60)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97-107.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529-538.
3. Standring DN, Bridges EG, Placidi L, et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother. 2001;12(Suppl 1):119-129.
4. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med. 2007;356(25):2614- 2621.
5. Sasadeusz J, Audsley J, Mijch A, et al. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. Aids. 2008;22(8):947-955.
6. Low E, Cox A, Atkins M, Nelson M. Telbivudine has activity against HIV-1. Aids. 2009;23(4):546-547.
7. Zhou XJ, Fielman BA, Lloyd DM, Chao GC, Brown NA. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Antimicrob Agents Chemother. 2006;50(7):2309-2315.
8. Zhou XJ, Lloyd DM, Chao GC, Brown NA. Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J Clin Pharmacol. 2006;46(3):275-281.
9. Zhou XJ, Swan S, Smith WB, et al. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 2007;51(12):4231-4235.
10. Tyzeka. Package Insert. Cambridge, MA: Idenix Pharmaceuticals, 2009.
11. Zhou XJ, Marbury TC, Alcorn HW, et al. Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment. Antimicrob Agents Chemother. 2006;50(5):1721-1726.
12. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med. 2009;150(2):104-110.
13. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45(2):507-539.
14. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357(25):2576-2588.
15. Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology. 2008;47(2):447-454.
16. Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med. 2007;147(11):745-754.
17. Wang Y, Jia J, Hou J, et al. A phase III comparative trial of telbivudine vs lamivudine in Chinese patients with chronic hepatitis b: two year results. Gastroenterology. 2007;132(4 Suppl 1):A-763.
18. Gane EJ, Wang Y, Buti M, et al. Continued telbivudine treatment results in high rates of maintained response in HBeAg-positive patients at 3 years. Hepatology. 2008;48(4 Suppl):A729.
19. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136(2):486-495.
20. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol. 2006;44(2):283-290.
21. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. November 3, 2008. Available at: http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf. Accessed March 8, 2009.
22. Delaney WEt, Yang H, Miller MD, Gibbs CS, Xiong S. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother. 2004;48(10):3702-3710.
23. Patty A, Li B, Serra I, Standring DN, Seifer M. In vitro anti-HBV activity of telbivudine/tenofovir and telbivudine/entecavir combinations. Hepatology. 2007;46(4 Suppl 1):A663.
24. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129(2):528-536.
25. Sung JJ, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol. 2008;48(5):728-735.
26. Matthews GV, Avihingsanon A, Lewin SR, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology. 2008;48(4):1062-1069.
27. Bridges EG, Selden JR, Luo S. Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B. Antimicrob Agents Chemother. 2008;52(7):2521-2528.
28. Brown CA, Smith F, Laessig K. Creatine kinase (CK) elevations and muscle toxicities associated with chronic telbivudine use in prospective clinical trials. Hepatology. 2007;46(4 Suppl 1):A655.
29. Zhang XS, Jin R, Zhang SB, Tao ML. Clinical features of adverse reactions associated with telbivudine. World J Gastroenterol. 2008;14(22):3549- 3553.
30. Colacino JM. Mechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU). Antiviral Res. 1996;29(2-3):125-139.
31. McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995;333(17):1099-1105.
32. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol. 2005;42(3):302-308.
33. Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat. 2004;11(5):432-438.
34. Shouval D, Lai CL, Chang TT, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy. J Hepatol. 2009;50(2):289-295.
35. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001;33(6):1527- 1532.
36. Matthews GV, Bartholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. Aids. 2006;20(6):863-870.
37. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999;30(5):1302-1306.
38. Tenney DJ, Pokornowski KA, Rose RE, et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients. Gastroenterology. 2009;136(5 Suppl 1):A865.
39. Audsley J, Arrifin N, Yuen LK, et al. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations. HIV Med. 2009;10(4):229-235.
40. Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther. 2005;10(6):727-734.
41. Snow-Lampart A, Chappell BJ, Curtis M, et al. Week 96 resistance surveillance for HBeAg-positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300 mg QD. Hepatology. 2008;48(4 Suppl 1):A745.
42. Benhamou Y, Fleury H, Trimoulet P, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology. 2006;43(3):548-555.
43. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131(6):1743-1751.
44. Heathcote EJ, Gane E, Lai C, et al. Salvage therapy with adefovir for virologic breakthrough in telbivudine-treated patients from the GLOBE study. Gastroenterology. 2007;132(4 Suppl 1):A765.
45. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 1996;24(3):714-717.
46. Seifer M, Patty A, Serra I, Li B, Standring DN. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. Antiviral Res. 2009;81(2):147-155.
47. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001-1010.
48. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology. 2006;44(6):1656-1665.
49. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354(10):1011-1020.
50. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother. 2004;48(9):3498-3507.
51. Colonno R, Rose RE, Pokornowski K, et al. Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients. J Hepatol. 2007;46(Suppl 1):S294.
52. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 2003;125(2):292-297.
53. Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol. 2008;48(5):747-755.
54. Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology. 2009;49(4):1158-1165.
55. Fung SK, Mazzulli T, Sherman M, Popovic V, Sablon E. Presence of rtA194T at baseline does not reduce efficacy to tenofovir (TDF) in patients with lamivudine (LAM)-resistant chronic hepatitis B. Hepatology. 2008;48(4(Suppl)):A699.
56. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6(12):1315-1341; quiz 1286.
57. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283.
58. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol. 2009;50(2):227-242.
59. Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol. 2009;51(1):11-20.
60. Pharmasset. Pharmasset voluntarily halts clinical studies with clevudine in hepatitis B infected patients [Press Release]. April 20, 2009. Available at: http://investor.pharmasset.com/releasedetail.cfm?releaseID=378789. Accessed June 18, 2009.